VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo

VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo

Objective: We aimed to develop a novel anti-HIF-1α intrabody to decrease gemcitabine resistance in pancreatic cancer patients. Methods: Surface plasmon resonance and glutathione S-transferase pull-down assays were conducted to identify the binding affinity and specificity of anti-HIF-1α VHH212 [a si...

Full description

Bibliographic Details
Main Authors: Guangbo Kang, Min Hu, He Ren, Jiewen Wang, Xin Cheng, Ruowei Li, Bo Yuan, Yasmine Balan, Zixuan Bai, He Huang
Format: Article
Language:English
Published: China Anti-Cancer Association 2021-08-01
Series:Cancer Biology & Medicine
Subjects:
pancreatic cancer
nanobody therapeutic
intracellular antibody
hif-1α
inhibitor
gemcitabine
chemosensitizer
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/1837

Internet

http://www.cancerbiomed.org/index.php/cocr/article/view/1837

Similar Items